This new article publication from Acta Pharmaceutica Sinica B , discusses a bispecific killer engager for targeted depletion ...

Cellistic introduces Echo-NK Platform to enable scalable manufacturing of allogeneic cell therapies to target multiple diseases: Mont-Saint-Guibert, Belgium Monday, April 14, 2025 ...

Technological advances empower the modification of NK cells and renewed potential for therapeutic uses in cancer and ...

A novel cell therapy approach using cord blood-derived natural killer (NK) cells pre-complexed with AFM13, or acimtamig, a ...

Yago Nieto, MD, PhD, discusses AFM13, how it works, and its effect as a bispecific antibody that targets CD30 and CD16.

The bone marrow environment evolves in ways that support the cancer, and I’m a firm believer that to treat cancer effectively ...

Inga Rødahl from the Center for Infectious Medicine (CIM) at the Department of Medicine, Huddinge (MedH) is defending her ...

The team identified a monoclonal antibody called KG2032 that ... NK Cells Complexed With Bispecific Antibody Yield High Response Rates in Patients With Lymphoma Apr. 4, 2025 — A novel cell ...

Natural killer cell deficiency should be considered in patients susceptible to herpes virus or papillomavirus with persistently decreased NK cell function.

The following is a summary of “FcγR3A polymorphism influences natural killer cell activation and response to anti-PD-L1 ...

Senti Biosciences, Inc.’s SNTI share price has surged by 8.89%, which has investors questioning if this is right time to sell.

A novel cell therapy approach using cord blood-derived natural killer (NK) cells pre-complexed with AFM13, or acimtamig, a CD30/CD16A bispecific antibody, was safe and generated strong response ...